Mesenchymal stem cell therapy in the treatment of acute and chronic graft versus host disease.

Mesenchymal stem cells (MSC) are a cellular component of the supportive microenvironment (stroma) found in the bone marrow, umbilical cord, placenta, and adipose tissues. In addition to providing cellular and extracellular cues to support the proliferation and differentiation of cells that comprise functional tissues, MSC also contribute to tissue repair and have immunomodulatory properties. Their ability to modulate immunologic reactions while themselves not provoking immunologic responses from alloreactive T-lymphocytes and/or other effector cells, make MSC a potentially ideal therapeutic agent with which to treat graft versus host disease (GvHD) following hematopoietic transplantation. Despite in vitro experiments confirming that MSC suppress mixed lymphocyte reactions (MLR) and in vivo evidence from mouse models that show evidence that MSC can ameliorate GvHD, clinical trials to date using MSC to treat GvHD have shown mixed results. Whether this is a consequence of suboptimal timing and dose of administered MSC remains to be clarified. It is clear that immunomodulatory potential of MSC as a cellular therapy for GvHD remains to be realized in the clinic.

Introduction

Mesenchymal stem cells (MSC) are a population of phenotypically heterogeneous cells that are an important cellular component of the supportive stromal microenvironment within functional tissues. They have the capacity to differentiate into osteoblasts, chondroblasts, and adipocytes in vitro (Pittenger et al., 1999; Jiang et al., 2002; Horwitz et al., 2005; Dominici et al., 2006) and since they do not express class II human histocompatibility antigens (HLA-II), or accessory molecules (CD40, CD80, and CD86) they do not provoke an immunologic response if transplanted. As a consequence, HLA matching does not present as a major hurdle against their use in cellular therapies (Le Blanc et al., 2003). In addition, MSC have the capacity to modulate immune reactions (Di Nicola et al., 2002; Aggarwal and Pittenger, 2005; Ramasamy et al., 2008; Uccelli et al., 2008), are important for effective tissue repair and regeneration (Deans and Moseley, 2000; Horwitz et al., 2002; Toma et al., 2002) and can be isolated, expanded, and purified ex vivo, from many tissues including bone marrow (McNiece et al., 2004; Robinson et al., 2006; Najar et al., 2010a), umbilical cord (Majore et al., 2011; Najar et al., 2010a,b; Tong et al., 2010), placenta (Zhang et al., 2004a), and adipose tissue (Najar et al., 2010a,b). Since immunoprivileged MSC do not provoke immunologic responses in an HLA-unmatched recipient and are able to modulate immunologic interactions, they are an attractive candidate as a potential cellular therapy for the treatment of graft versus host disease (GvHD). GvHD remains a significant cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation and any therapy that might ameliorate or eliminate the symptoms of GvHD, especially steroid-refractory GvHD, would have great clinic significance.

MSC as Immunomodulators

Mesenchymal stem cells possess intrinsic immunoregulatory activities that, while not yet fully characterized, broadly modulate innate and adaptive immune responses (Uccelli et al., 2008; Auletta et al., 2010). Within the context of innate immunity, MSC alter antigen-presenting cell (APC) development, maturation, and function. Dendritic cells (DC) are potent APC for naïve T-cells, and are critical in donor T-cell activation during acute GvHD (Shlomchik, 2007). MSC inhibit differentiation of monocytes to DC, and furthermore, affect DC differentiation, activation, and function (Uccelli et al., 2008). MSC also inhibit natural killer (NK) cell proliferation and cytokine production, and could potentially modulate DC function through their effects on NK cells (Spaggiari et al., 2006). In the light of these effects, MSC might suppress allo-reactivation of donor T-cells against the host in the setting of GvHD, although acute GvHD typically results in high levels of interferon gamma (IFNγ) which may increase MHC class II expression on MSC (Shlomchik, 2007; Welniak et al., 2007) and could paradoxically compound the development of GvHD.

Within the context of adaptive immunity, MSC inhibit alloreactive T-cell responses via contact-dependent mechanisms and soluble factors (Keating, 2008; Uccelli et al., 2008). Some studies suggest MSC effect a shift in T-cell function toward a more regulatory phenotype (Prevosto et al., 2007). Importantly, the effects of MSC on T-cells are independent of HLA matching between MSC and lymphocytes (Le Blanc et al., 2003; Sundin et al., 2009) and MSC can be administered repeatedly without provoking an immunologic response from the recipient (Sundin et al., 2009).

MSC and Tissue Repair

Currently, the role of MSC in tissue repair and regeneration is under extensive study. Of specific relevance to mechanisms associated with the development of GvHD, a number of animal models of injury including cerebral ischemia (Li et al., 2010), total body irradiation (Chapel et al., 2003; Devine et al., 2003), and myocardial infarction (Pittenger and Martin, 2004) have demonstrated a chemotactic response of MSC to the site of injury. Such sites of injury might include lesions associated with GvHD. Once at the site of injury, or inflammation, it has been proposed that MSC can stimulate tissue repair (Prockop and Olson, 2007).

Immunomodulatory Role for MSC in Murine Models of GvHD

Murine models have been used to investigate the immunomodulatory potential of MSC in ameliorating (preventing and/or treating) GvHD. Such studies have revealed a mix of results with some showing immunomodulatory efficacy and others not (Chung et al., 2004; Sudres et al., 2006; Min et al., 2007; Tisato et al., 2007). However, they have highlighted a number of important questions which might impact the clinical efficacy of MSC as a cellular therapy for GvHD. Such questions include:

Defining the optimal dose of MSC,

Determining the correct time for administration of MSC, and

Studying the biodistribution of MSC.

Defining the optimal dose of MSC: Given that the number of MSC available for transplant is likely a limiting factor, the target doses that should be utilized to ameliorate GvHD in the clinic become an important consideration. Using the mixed lymphocyte reaction (MLR) optimal inhibition of splenocyte proliferation was achieved in the presence of MSC at a ratio of 0.5–1 MSC: 1 splenocyte (Joo et al., 2010). MSC were administered into a murine model of GvHD at this ratio. GvHD was established in lethally irradiated BALB/c mice when 5 × 106 bone marrow cells and 1 × 106 spleen cells from C3H/he donor mice were injected. In this model, death occurred after 12 days due to severe acute GvHD. Against this background, mice also received 0.5 × 106 MSC (low dose), 1.0 × 106 MSC (intermediate dose), or 2.0 × 106 MSC (high dose) at the time that 1 × 106 spleen cells were infused. These doses reflect MSC:splenocyte ratios of 0.5:1, 1:1, and 2:1. While the low dose of MSC did not prevent death, the survival rate of mice receiving the intermediate and high doses of MSC were significantly improved (Joo et al., 2010).

Consistent with previous findings (Casiraghi et al., 2008; Di Ianni et al., 2008; Ye et al., 2008; Gonzalez-Rey et al., 2010), the beneficial impact of MSC administration in this GvHD model appeared to be, at least in part, to an MSC-associated activation of regulatory T-cells (TReg). Indeed, an increase in TReg numbers (CD4+25+Foxp3+ cells) was observed in vivo in mice receiving both splenocytes and MSC as compared to those receiving splenocytes alone (Joo et al., 2010). It is thought that TGFβ secreted by the MSC may induce the proliferation and activation of TReg (Keating, 2008; Uccelli et al., 2008). Increased TReg activity is ultimately thought to suppress the activity of the donor T-cells that are ultimately responsible for the acute GvHD observed, thereby ameliorating the symptoms of the disease and improving the survival rate of the mice. The amount of any immunoregulatory factor liberated by the MSC is proportional to the numbers of MSC, therefore it is likely that a specific dose of MSC might be required before levels sufficient to maximally stimulate TReg proliferation and ameliorate the symptoms of GvHD are achieved in vivo. Recent data have further confirmed that there is an interaction between MSC and TReg (Kavanagh and Mahon, 2011). In this instance, MSC induce the proliferation and activation of TReg in vivo and reduce a specific allergen-driven pathology.

Determining the correct time for administration of MSC: Experiments have been performed to investigate the optimal timing for administration of MSC to best ameliorate the symptoms of GvHD. A murine GvHD model was generated by the transplant of lethally irradiated male BALB/c (H-2Kd) mice with bone marrow and splenocytes from female C57BL/6 (H-2Kb) mice (Polchert et al., 2008). MSC were introduced into this model concurrently with bone marrow infusion, or 2, 20, or 30 days after bone marrow infusion. While mice died of the symptoms of acute GvHD when they received no MSC, death was also observed when MSC were administered at the time of bone marrow infusion (early time point), or 30 days after bone marrow infusion (late time point). However, when MSC were administered 2, or 20 days after bone marrow infusion, significantly increased survival rates were observed indicating that the administered MSC acted to ameliorate the symptoms of the acute GvHD (Polchert et al., 2008). The apparent failure of MSC to ameliorate the symptoms of GvHD when administered early (<2 days) was possibly due to levels of immunomodulatory factors being too low to elicit any beneficial effect. The apparent failure of MSC to ameliorate the symptoms of GvHD when administered later (30 days) was possibly attributable to the presence of overwhelming numbers of activated T-cells at this time point. To explain the apparent “window” of opportunity for effective MSC immunomodulation of GvHD and significantly increased survival rates (observed at 2 and 20 days after bone marrow infusion), it is suggested that a pro-inflammatory milieu needs time to develop. Within this milieu the MSC become activated. MSC are activated by IFNγ (Croitoru-Lamoury et al., 2007) and their migration might be driven, at least in part, by an IFNγ-associated upregulation of chemokine receptors expressed by MSC (New et al., 2002; Wang et al., 2002). Once activated, MSC are possibly drawn to sites of T-cell activation where they may block interactions between donor T-cells and DC which may prevent the activation of the donor T-cells thereby ameliorating the symptoms of GvHD (Zhang et al., 2004b; Aggarwal and Pittenger, 2005; Beyth et al., 2005; Gur-Wahnon et al., 2007). The importance of IFNγ in this activation process was shown when bone marrow and splenocytes were transplanted from IFNγ knock-out mice. In the absence of IFNγ MSC were not activated and failed to immunosuppress the donor T-cells leading to the development of GvHD, irrespective of the time or dose of administration (Polchert et al., 2008). Given that IFNγ appears to have an important role in the activation of MSC and given that serum levels of IFNγ the factor remained low for up to 2 days after transplantation (Polchert et al., 2008), it is perhaps not a surprising observation that MSC administered early (<2 days) fail to ameliorate GvHD. These data provide strong evidence that the time of administration of MSC after transplant is a critical consideration if effective amelioration of GvHD is to be achieved.

Studying the biodistribution of MSC: Imaging can be used to reveal the biodistribution of MSC in murine models of GvHD (Joo et al., 2011). In one such model, recipient BALB/c-nude mice received a lethal 500 cGy radiation dose and 5 × 106 BM cells from normal C57BL/6 donor mice. To induce GvHD, 1 × 106 splenocytes from C57BL/6 donor mice expressing the enhanced green fluorescent protein (EGFP) was injected. EGFP signal allowed the trafficking of splenocytes and identified sites of GvHD in situ. To study the biodistribution of MSC in this model, MSC were generated from C57BL/6 donor mice expressing red fluorescent protein (RFP). RFP-MSC were transplanted at 1 × 106 MSC/mouse. All cells were injected into the lethally irradiated BALB/c-nude mice within 24 h of irradiation. After 2 days, EGFP signal, associated with donor splenocytes, was detected in the lungs. At this same time point RFP signal associated with MSC was also detected in the lungs (Gao et al., 2001; Lee et al., 2009; Joo et al., 2011). After 7 days, EGFP (splenocyte) signal intensity reduced in the lungs and increased in the GI tract. A similar change in the pattern of RFP (MSC) signal intensity was observed. After 22–37 days, EGFP and RFP signals co-localized to the liver, skin, and lymph nodes, illustrating that MSC can home to sites of progressive and on-going GvHD and thereby potentially exert direct cell-cell contact mediated and/or indirect paracrine immunosuppressive effects.

No Evidence of an Immunomodulatory Role for MSC in a Canine Model of GvHD

While the mouse provides genetically well-defined models with which to investigate the immunomodulatory role of MSC against experimentally induced GvHD in vivo, the use of less rigorously defined models might be more representative of clinical transplantation. When such a model (canine) is used, researchers report no benefit associated with MSC administration in the treatment of GvHD and prevention of graft rejection (Mielcarek et al., 2011). These negative observations were made despite the demonstration of in vitro suppressive activity in canine MLR experiments by allogeneic canine MSC and despite the observation that that the pattern of allogeneic canine MSC distribution in vivo in canine recipients was similar to that observed in mice after intravenous administration of mouse MSC (namely accumulation in lungs immediately after administration followed by redistribution to GI tract, liver, spleen and bone marrow). The failure to demonstrate any benefit associated with MSC administration in this dog model also occurred despite frequent, repeated MSC administration (2–3 doses/week) at doses of up to 30 × 106 MSC/kg which is somewhat inconsistent with data from murine studies which suggest that timing and dose of MSC administration are critical if optimal immunomodulation of GvHD by MSC is to be achieved (Mielcarek et al., 2011).

Clinical Trials with MSC to Treat GvHD

Clinical trials were developed based on the pre-clinical data with the limitations inherent to murine models (summarized in Tables 1–3). MSC therapies have been most extensively studied in steroid-refractory GvHD. The first case of successful treatment of severe refractory acute GvHD of the gut and liver in a pediatric patient using ex vivo expanded haplo-identical human MSC was reported by Le Blanc et al. (2004). While a prompt amelioration of GvHD was observed after the administration of MSC, symptoms recurred. However, these symptoms were responsive to a second administration of MSC (Le Blanc et al., 2004). Of eight patients with steroid-refractory GvHD that were subsequently treated with MSC a complete response (CR) was achieved in six patients (75%). One month after MSC administration, analysis of a colon biopsy from one of the six patients in CR revealed DNA from the donor MSC (Ringden et al., 2006). These encouraging results were subsequently corroborated in a non-randomized, multicenter trial reported by the European Blood and Marrow Transplant MSC consortium (Le Blanc et al., 2008).

Table 1

Results of clinical trails utilizing MSC for steroid-refractory acute G.

Study	N	Age (range)	GvHD organ/grade	MSC source	Passage/media	Dose (M, 106 MSC)/schedule	Results
Ringden et al. (2006)	8	56 (8–61)	All GlGrade III: 6Grade IV: 2	BM, third party/slb/haplo	1–4/FBS	1 M/kg (range 0.7–9); 1 dose, n = 5; 2 dose, n = 3	6/8 CR (1/2 kids); 5/8 OS; no infusional toxicity; one disease relapse
Fang et al. (2007)	6	39 (22–49)	S+L or Gl Grade III: 2Grade IV: 4	Adipose, third party/haplo	5/FBS	1 M/kg MSC; 1 dose, n = 5; 2 dose, n = 1	5/6 CR, 4/6 OS at 40 months; no infusional toxicity; one disease relapse
Le Blanc et al. (2008)	55	22 (0.5–64)	S10, GI 31, L2Grade II: 5Grade III: 25Grade IV: 25	BM, third party/slb/haplo	2 (1–4)/FBS	1.4 M/kg (range 0.4–9); 1 dose (range 1–5)	CR: 68% kids, 43% adults; PR: 16% kids, 17% adults; 2-year OS: 53% for CR vs. 16% others; no infusional toxicity; 3 relapse
Von Bonin et al. (2009)	13	58 (21–69)	All S+L+GIGrade III: 2Grade IV: 11	BM, third party	1–2/platelet lysate	0.9 M/kg (range 0.6–1.1); 2 doses (range 1–5);	2/13 CR, 5/13 mixed response; 4/13 OS at median 257 days; No infusional toxicity; no relapse
Muller et al. (2008)	2	4, 14	Grade II (S, Gl)Grade III (S, L, Gl)	BM, haplo/third party	Max 6 weeks culture/FBS	0.4 M/kg, 3 M/kg 1 dose	1 CR, 1 NR with subsequent relapse; no infusional toxicity
Lucchini et al. (2010)	8	10 (4–14)	Grade I: 3, SGrade II: 1,SGrade III: 0Grade IV: 4, Gl	BM, third party	Platelet lysate	1.2 M/kg (range 0.7–2.8); 1 dose	3/8 CR, 2/8 PR, 3/8 NR 5/8 OS; no infusional toxicity; no relapse
Kurtzburg et al. (2009)	59	8	Grade II: 6Grade III: 20Grade IV: 33	BM, third party (Prochymal)	5/FBS	2 M/kg; 8 biweekly × 4 weeks, followed by 4 infusions weekly × 4 if PR	64% ORR at day 28; 76 vs. 9% survival at day 100; no infusional toxicity
Martin et al. (2010)	260	44 MSC; 40 control	MSC/controlB: 38 vs. 23C: 88 vs. 50D: 47 vs. 14	BM, third party (Prochymal)	5/FBS	2 M/kg; 8 biweekly × 4 weeks, followed by 4 infusions wkly × 4 if PR	No diff in durable CR between MSC and control; liver, Gl GvHD significantly better response 81 vs. 68%, p = 0.035

Table 3

Results of clinical trails utilizing MSC for chronic G.

Study	N	Age (range)	GvHD organ/grade	MSC source	Passage/media	Dose (M, 106 MSC)/schedule	Results
Muller et al. (2008)	3	15 (15–17)	Extensive chronic	BM, third party/sib/haplo	Max 6 weeks culture/FBS	2.0 M/kg (range 1.4–3.0); 1 dose, n = 1; 2 dose, n = 2	1/3 improvement; no infusional toxicity; no relapse
Lucchini et al. (2010)	5	9 (5–15)	Chronic skin + mucosa, n = 4; chronic skin + liver, n = 1	BM, third party	expanded in platelet-lysate medium	1.1 M/kg (range 0.7–1.4); 1 dose, n = 4; 2 dose, n = 1	1/5 CR with reflare, 2/5 PR, 2/5 NR; no infusional toxicity; no relapse; in vivo immunomodulation noted in responsive group
Zhou et al. (2010)	4	42 (38–43)	Extensive, sclerodermal features	BM, third party	3–6/FBS	1–2 × 107MSC/kg; 4–8 intra-BM injections per patient	4/4 significant improvement; no infusional toxicity
Weng et al. (2010)	19	29 (18–39)	Extensive chronic	BM, third party	2–3/FBS	0.6 M/kg (range 0.2–1.4); 1–5 doses	74% ORR (4 CR, 10 PR), five patients able to stop immunosuppression, 2 year OS 78%; in vivo immunomodulation noted in responsive group

European Blood and Marrow Transplant MSC Study

The EBMT MSC trial shared expansion protocols and common reagents and 25 pediatric and 30 adult patients with steroid-refractory GvHD were treated with MSC. MSC were derived from HLA-identical and haplo-identical sibling donor bone marrow, or third-party mismatched, bone marrow. A single median dose of 1.4 × 106 MSC/kg was given and a 70% initial response rate (complete or partial remission) was achieved. First response was observed after a median of 18 days of MSC administration. Patients that responded to the MSC therapy and achieved CR at 6 weeks had a statistically significant reduced level of treatment-related mortality (TRM) at the 1-year time point when compared to patients that did not respond (37 vs. 72%, P = 0.002, respectively). Further, overall survival (OS) was also significantly improved in patients in CR after MSC therapy, when compared to patients that did not respond (53 vs. 16%, P = 0.018, respectively; Le Blanc et al., 2008). MSC infusions were well tolerated and no significant adverse events were reported. Responses in pediatric patients were generally better than adult patients, with a statistical improvement in survival achieved. Since most patients received third-party (unmatched) donor MSC and achieved encouraging amelioration of GvHD, these data suggests that any concerns regarding HLA disparity between donor and recipient are of little significance.

Phase II Clinical Trials of Third-Party MSC to Ameliorate Steroid-Refractory Acute GvHD

Further to the EBMT MSC trial, a pediatric phase II study of third-party, “off-the-shelf,” mismatched MSC (Prochymal®, Osiris Therapeutics, Inc.) for steroid-refractory acute GvHD has also been reported (Table 1). Fifty-nine patients (median age 8 years) with steroid-refractory acute GvHD received 8 biweekly infusions of 2 × 106 MSC/kg for 4 weeks, followed by an additional 4 weekly infusions as “maintenance.” The majority of patients presented with severe gut and liver GvHD, and had received prior therapy for GvHD. At day 28, the overall response rate was 64% and patients that showed responses had a significantly better survival at the 100 day time point (76 vs. 9%) as compared to patients who did not (Kurtzberg et al., 2009). Similar findings have been reported in other studies (Table 1; von Bonin et al., 2009).

MSC as an Adjunct to Steroid Therapy in the Treatment of Steroid Responsive Acute GvHD

While there are many reports of the use of MSC to treat steroid-refractory GvHD (Table 1), there are fewer studies of MSC as an adjunct therapy for the treatment of steroid responsive acute GvHD (Table 2). The results of such a phase II trial for patients with grades II-IV acute GvHD have been reported (Kebriaei et al., 2009). Thirty-two adult patients received two treatments of MSC (Prochymal®) at a dose of either 2 or 8 × 106 MSC/kg in combination with a conventional corticosteroid regimen. Patients continued to receive GvHD prophylaxis with tacrolimus, cyclosporine, or mycophenolate mofetil. Thirty-one patients were evaluable, with 94% initial response rate noted (24 CR, 5 PR). Nineteen of 24 CR were maintained for at least 90 days. No infusional toxicities or ectopic tissue formation were reported. While the trial was not designed to detect differences between the two MSC doses administered, no obvious differences were observed (Kebriaei et al., 2009).

Table 2

Results of clinical trails utilizing MSC for .

Study	N	Age (range)	GvHD organ/grade	MSC source	Passage/media	Dose (M, 106 MSC)/schedule	Results
Kebriaei et al. (2009)	32	52 (34–67)	Grade II: 21Grade III: 8Grade IV: 3	BM, third party (Prochymal)	5/FBS	2 or 8 M/kg at 1 and 3 days after GvHD + steroids	94% initial response (77% CR, 16% PR), 61% sustained CR; No difference between high/low MSC dose; No infusional toxicity; three disease relapse
Osiris Therapeutics, Inc. (2009)	192	18–70	B–D	BM, third party (Prochymal)	5/FBS	2 M/kg; twice wkly × 2 weeks, followed by weekly × 2; MSC vs. placebo	No difference in durable CR between MSC and placebo, 45 vs. 46%

Phase III Clinical Trials of Third-Party MSC to Ameliorate Steroid Sensitive and Steroid-Refractory Acute GvHD

Preliminary results from two multicenter, randomized, phase III clinical trials for de novo acute and steroid-refractory acute GvHD have been reported by Osiris Therapeutics, Inc. (2009). In both studies, third party, “off-the-shelf” MSC (Prochymal®) were administered weekly or biweekly for 4 weeks with individual dosing at 2 × 106 MSC/kg. Neither the steroid-refractory nor the newly diagnosed GvHD trials reached the primary endpoint of durable CR ≥ 28 days. However, select patients with steroid-refractory liver or gastrointestinal GvHD were reported to have significantly improved response rates (81 vs. 68%, P = 0.035). No significant difference was noted with respect to toxicity or recurrent malignancy rates (Martin et al., 2010).

MSC as a Cellular Therapy to Ameliorate Chronic GvHD

Experience with MSC for the treatment of chronic GvHD is more limited, and summarized in Table 3. One pediatric patient showed slight improvement after infusion of 3 × 106 MSC/kg administered 7 and 26 months after transplant (Muller et al., 2008). A second patient with extensive chronic GvHD was treated with 0.6 × 106 haplo-identical MSC/kg 5 months after transplant, but showed no response (Ringden et al., 2006). Of note, this patient and a patient with chronic GvHD treated with MSC in a previous study, died eventually of complications associated with the development of EBV-PTLD (Ringden et al., 2006; Muller et al., 2008). Consistent with observations that suggest only limited (if any) improvement in chronic GvHD following MSC infusion, reports from other pediatric patients with chronic GvHD of skin and mucosa treated with “off-the-shelf” MSC, reveal a limited transient benefit following MSC administration (Lucchini et al., 2010). Partial responses and a CR that subsequently reflared were reported in this instance. The median MSC dose delivered was 1.2 × 106/kg (range 0.7–2.8 × 106/kg) as a single infusion at a median of 5 months following transplant (range 1–10 months; Lucchini et al., 2010).

In contrast, significant improvements have been reported following MSC therapy in patients with sclerodermal-type chronic GvHD (Zhou et al., 2010). Patients with extensive skin changes and ulcers showed significant improvement when treated with four to eight intra-bone marrow injections of MSC at a dose of 1–2 × 107 MSC/kg. One change noted following MSC administration and possibly associated with the improvement in the symptoms of chronic GvHD was a reversal in the Th1 to Th2 lymphocyte ratio. The administration of MSC and improvement in chronic GvHD was associated with an increase in the proportion of Th1 lymphocytes and a reduction in the proportion of Th2 lymphocytes (Zhou et al., 2010).

Concerns Regarding the Use of FBS for the ex vivo Culture of a Clinical-Grade Human MSC Product

While FBS is widely used to supplement medium used to expand MSC in vitro there are concerns that the use of xenogeneic material may transmit infectious (viral or prion) agents and/or compromise the immunoprivileged nature of the MSC by the presence of antigenic xenogeneic proteins on their cell surface (Sundin et al., 2007). In light of these concerns, human-derived alternatives to FBS have been investigated including autologous and allogeneic human serum and human platelet lysate (Stute et al., 2004; Doucet et al., 2005; Lin et al., 2005; Shahdadfar et al., 2005; Muller et al., 2006; Kocaoemer et al., 2007; Bieback et al., 2009; Lucchini et al., 2010). While ex vivo expansion of human MSC in medium supplemented with autologous or allogeneic human serum is highly variable and unreliable (Oreffo et al., 1997; Kuznetsov et al., 2000; Yamaguchi et al., 2002; Shahdadfar et al., 2005), the use of pooled human platelet lysate (hHPL) has proven more consistent supporting both the growth and differential potential of MSC (Schallmoser et al., 2007; Bieback et al., 2009; Lucchini et al., 2010). Outside of the use of xenogeneic or allogeneic supplements for basal media, a number of defined serum-free media have been developed specifically for the culture of human MSC (e.g., MesenCult®-XF, StemCell Technologies; Hartmann et al., 2010). Although extensive comparison remains to be performed, the performance of these specialized serum-free media is reported to be comparable to that obtained with media supplemented with FBS (Hartmann et al., 2010).

Summary

Despite the evidence from in vitro MLR studies in multiple species demonstrating that MSC have immunomodulatory activity, and from well-defined mouse models demonstrating the ability of MSC to ameliorate the symptoms of GvHD and to improve survival following hematopoietic transplantation, attempts to duplicate these observations in a clinical hematopoietic transplantation setting have proven less successful. While this might be a consequence of suboptimal dosing and/or timing of MSC administration relative to the development of GvHD in patients (factors highlighted as critical for efficacy by studies in mouse models), attempts to duplicate these observations in less well-defined animal (canine) hematopoietic transplantation models have similarly shown little benefit to the administration of MSC, despite the use of numerous dosing and timing variables. These inconsistencies indicate that further studies are required. Optimal culture and manufacturing conditions for the generation of sufficient numbers of an “off-the-shelf” GMP-grade MSC product need to be identified and standardized for MSC to provide an effective means by which to improve the significant mortality and morbidity currently associated with GvHD. As discussed, while there are concerns associated with the use of xenogeneic fetal serum for the culture of human MSC, MSC growth in allogeneic human serum is unreliable. Alternatives to the use of xenogeneic or human sera to supplement basal media include the use of human platelet lysate (hHPL) which provides factors necessary for MSC growth, while more complex serum-free proprietary media are also becoming available. More multicenter clinical trials with well-defined protocols, GMP-grade MSC products and clinical endpoints will ultimately allow for a better understanding of the potential therapeutic potential of MSC to evolve for the treatment of GvHD following hematopoietic transplantation.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.